Targeting PTSD with ultramicronized palmitoylethanolamide: Results from a randomized trial integrating...

Post-Traumatic Stress Disorder (PTSD) is a debilitating psychiatric condition with limited pharmacological options and high rates of partial response to cognitive behavioral therapy (CBT), the current gold standard. Recent evidence implicates the endocannabinoid system and neuroinflammation in PTSD pathophysiology. Palmitoylethanolamide (PEA), an endogenous lipid mediator with anti-inflammatory and neuroprotective properties, has emerged as a promising candidate for mitigating PTSD symptoms, in particular when administered in its ultramicronized formulations (PEA-um).

In a randomized, placebo-controlled clinical trial, 60 patients diagnosed with PTSD according to DSM-5 criteria were assigned to one of four treatment arms: PEA-um, PEA-um + CBT, placebo and placebo + CBT. Participants were assessed at five-time points over 18 months using the PTSD Checklist for DSM-5 (PCL-5) and the Hamilton Anxiety Rating Scale (HAM-A). Statistical analysis was conducted using Generalized Linear Mixed Models (GLMMs), controlling for age and gender.

All active treatments resulted in a significant reduction of PTSD and anxiety symptoms, with the PEA-um + CBT group showing the most pronounced and sustained improvements. At 18 months, mean PCL-5 and HAM-A scores in this group decreased from 67,3 ± 1,77 to 20,0 ± 2,12 and 49,6 ± 1,21 to 19,4 ± 1,81, respectively. Significant time × group interaction effects were observed (p < 0,0001), and no serious adverse events were reported.

The findings support the efficacy of PEA-um, particularly in combination with CBT, in alleviating PTSD symptoms. The results align with preclinical data highlighting PEA's role in modulating neuroinflammatory pathways and emotional regulation.

PEA-um, especially when combined with CBT, represents a promising and well-tolerated adjunctive treatment for PTSD, warranting further validation in larger clinical trials.